Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | FABP1 | P07148 | 1/20 | 0.44 |
| ▸ | FABP6 | P51161 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gapromidine SCHEMBL1818477 | 0.81 | CYP1A2 (0.44) | CYP1A2CYP2C19APPCXCR4FABP1 | |
| SCHEMBL7973029 | 0.80 | ALDH1A1 (0.52) | CYP1A2APPHRH3ALDH1A1HPGD | |
| SCHEMBL27513658 | 0.80 | CYP1A2 (1.00) | CYP1A2CYP2C19APPCXCR4FABP1 | |
| SCHEMBL7971482 | 0.78 | ALDH1A1 (0.41) | CYP1A2CYP2C19ALDH1A1KDM4EHPGD | |
| SCHEMBL7430372 | 0.77 | CYP2C19 (0.42) | CYP1A2CYP2C19APPCXCR4FABP1 | |
| Gapromidine SCHEMBL7430377 | 0.77 | CYP1A2 (0.40) | CYP1A2 | |
| Hydrochloric Acid SCHEMBL7429034 | 0.77 | CYP2C19 (0.41) | CYP1A2CYP2C19APPCXCR4FABP1 | |
| Gapromidine SCHEMBL10372400 | 0.77 | CYP1A2 (0.40) | CYP1A2HRH3 | |
| SCHEMBL7971404 | 0.76 | HRH4 (0.43) | CYP1A2HRH3 | |
| SCHEMBL3265804 | 0.75 | CYP1A2 (0.70) | CYP1A2CYP2C19CXCR4FABP1FABP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE37303-E1 | Imidazole compounds and their therapeutic applications | INSTITUT NATIONAL DEL LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2001-07-31 | — | — | US | claimed |
| EP-0597088-A1 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1994-05-18 | — | — | EP | claimed |
| WO-1993014070-A2 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1993-07-22 | — | — | WO | claimed |
| US-9023818-B2 | Pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use | GLYCON LLC (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140057869-A9 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | IMI INTERNATIONAL MEDICAL INNOVATIONS, INC. | 2014-02-27 | — | — | US | disclosed |
| US-20110237544-A1 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | CHRISTIAN SAMUEL T | 2011-09-29 | — | — | US | disclosed |
| US-RE37303-E1 | Imidazole compounds and their therapeutic applications | INSTITUT NATIONAL DEL LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2001-07-31 | — | — | US | disclosed |
| EP-0700519-B1 | A METHOD OF DETERMINING AFFINITY AND KINETIC PROPERTIES | BIACORE AKTIEBOLAG (SE) | 2000-10-18 | — | — | EP | disclosed |
| US-5753518-A | Method of determining affinity and kinetic properties | PHARMACIA AB (SE) | 1998-05-19 | — | — | US | disclosed |
| US-5559113-A | ANTAGONISTS TO HISTAMINE H3 RECEPTORS, SEDATIVES, ANTICONVULSANTS, ANTIULCER AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | 1996-09-24 | — | — | US | disclosed |
| EP-0700519-A1 | A METHOD OF DETERMINING AFFINITY AND KINETIC PROPERTIES | Biacore Aktiebolag (SE) | 1996-03-13 | — | — | EP | disclosed |
| WO-1994028416-A1 | A METHOD OF DETERMINING AFFINITY AND KINETIC PROPERTIES | PHARMACIA BIOSENSOR AB (SE) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237544-A1 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | CSGALNACT1, DDOST, STT3B | CYP1A2 2332/4885CYP2C19 844/4885APP 762/4885 |
| US-20140057869-A9 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use | CSGALNACT1, DDOST, STT3B | CYP1A2 2332/4885CYP2C19 844/4885APP 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.